Showing: 1 - 5 of 5 RESULTS

Gyms are open, but NYC’s still killing the independent-fitness-studio industry

Mr. Mayor, let’s get this straight: Indoor dining, indoor swimming, facials and gym workouts all got the green light to reopen, but ­Pilates, yoga and high-intensity interval-training classes remain a no-go?

How does Gotham’s healthiest industry remain shut down, months after the pandemic peaked? Our industry’s mission is to keep New Yorkers healthy through these crazy times, and we, of all businesses, are shuttered and forgotten about.

It’s baffling.

We are racking up rent bills from months spent waiting for our turn to open, with exactly zero revenue coming in. And now it isn’t clear whether that turn will come in this calendar year or the next.

Restaurants’ struggles have been front-page news for months, schools are finally open and Broadway is getting its bailout. But since we lack the size, organization and lobbyists, we aren’t getting any attention from you or your administration. What do we need to do to get a chance at survival?

There are more than 7,000 boutique fitness studios in the Big Apple that employ more than 100,000 taxpaying New Yorkers. Well, actually, we should say that there were 7,000 studios pre-pandemic — now it’s more like 6,000, and if we can’t open up in the next month, it will be more like 5,000.

An industry that was born in 2006 in New York City is now at risk of dying in 2020 on your watch. All you have to do to save the industry is let us open up with the same guidelines as our gym friends. You have deemed them fit to open, and we are just as safe.

Today, someone can go to a gym and run on a treadmill six feet away from the next runner. But the moment an instructor enters the picture, that same activity is illegal.

Again, baffling and bizarre. Since when is fitness at the gym any safer than fitness classes? There is absolutely zero evidence of group fitness being any more of a risk than gym fitness.

We can and would require masks and social distance. We would limit equipment sharing. We would implement contact tracing and upgrade our air filters to ensure our staff and clients are safe. Please, give us a chance to show you — and a fighting chance to survive this pandemic.

You claim to be a champion of small businesses, women and minorities — and guess what? We are all of those things. Many of us founders of firms are women, and a majority of our staff and clientele are also women.

In fact, 80 percent of the New Yorkers we serve are female. We employ diverse staff in our studios and our offices, and a majority of those folks are still unemployed. Why is it that male-friendly gym workouts can resume, but workouts with stronger female appeal are banned?

The longer we are shuttered, the harder it will be to bring back our out-of-work employees and our clients who’ve had to find an alternative way to stay fit — or,

PBM INDUSTRY REGULATION TO BE ARGUED BY SUPREME COURT

Patient Advocate Groups Optimistic Courts Will Support State Rights to Regulate

Washington, DC –News Direct– Alliance for Transparent & Affordable Prescriptions

As policy makers in Washington, DC debate the next appointee to the United States Supreme Court, patient advocate groups are optimistic existing Justices and the nominee will support rights of states to impose regulations on the Pharmacy Benefit Manager (PBM) industry. The case, Rutledge v. the Pharmaceutical Care Management Association, will argued before the Supreme Court on October 6, 2020. The Alliance for Transparent and Affordable Prescriptions (ATAP), a coalition of patient and provider groups concerned about the role PBMs play in the rising cost of drugs and reduced patient access to affordable treatment, filed an Amicus Brief with the United States Supreme Court in an effort to support the rights of states to impose regulations on the PBM industry.

ATAP’s Amicus Brief argues in part that PBMs are engaged in abusive practices with serious practical and policy consequences – including upward pressure on prescription drug pricing.

“The relationship that really matters is the doctor-patient relationship, not the relationship with the middlemen” stated Dr. Robert Levin, ATAP’s President. “Every day, we witness first-hand how the PBM industry drives up costs and interferes with patient access to the medications they need. Doctors, patients, and legislators are saying ‘enough is enough’ and are fighting back. We welcome the opportunity to lend our voice and arguments on behalf of patients as the Supreme Court weighs in on regulating this industry.”

The debate over the PBM industry is gaining traction in Washington as additional regulations are proposed, and even Presidential Executive Orders crafted in part to reign in PBM activity in the prescription drug marketplace.

“PBMs construct formularies and utilization management tools not based on science but on profit, often leading to higher drug prices,” Dr. Madeline Feldman of the Coalition of State Rheumatology Organizations (an ATAP member organization) stated. “The Supreme Court should agree to allow states to protect ALL patients from the machinations of PBMs – whose only fiduciary responsibility is to shareholders. Perhaps if the federal government demanded transparency and regulated PBMs appropriately, the states wouldn’t have to step up to do the job.”

“Countless healthcare stakeholders have waited eagerly for this day to come and will be closely watching the proceedings since this is the first case involving a PBM before the United States Supreme Court,” stated Kathleen A. Arntsen, President & CEO of Lupus and Allied Diseases Association (an ATAP member organization). “As a patient-led organization who represents people that deal with serious health conditions on a daily basis, we have firsthand experience with the frustration in struggling to access affordable and appropriate treatments due to the existence of the unnecessary middleman industry. We are thrilled that the Justices will finally weigh in on these momentous issues and hopeful that they will stand with patients and rule in favor of fair drug pricing.”

In an earlier statement on the matter, the plaintiff, Arkansas Attorney General

Future Care, Inc. Partners With 1Health.io to Bring Easy and Convenient COVID-19 Testing to the Maritime Industry

Saliva Tests Can Be Administered Anywhere, Helping the Shipping and Cruise Line Industries Return to Sea

Future Care, Inc., an international medical management and cost containment service provider exclusively to the maritime industry, today announced it has partnered with 1Health.io, the leading technology company that provides precision testing as a service, to provide saliva-based COVID-19 tests to ship owners, managers and crew members traveling to United States ports.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005103/en/

1Health.io empowers partners with the ability to offer convenient, non-invasive, and remote options for precision diagnostic testing. Partners can offer patients, customers or employees diagnostic testing that eliminates inconvenient or even risky visits to testing centers while also eliminating long wait times for results. 1Health.io’s platform allows partners, like Future Care, to launch their private, secure and scalable testing portal quickly, and to have tracking and reporting that is essential for supporting a large distributed team.

“Given that many of our clients are not based in the United States and their ships spend only a brief time in a US port our ability through 1Health.io to have the crew self-administer the test while here and see their results onboard ship or at home via the individual secure portal in 48 hours is a welcome resource for our clients,” said Christina DeSimone, Future Care’s President and CEO. “The 1Health.io testing platform has proved to be a gamechanger in maritime COVID-19 testing, and we fully expect that it will help the cruise ship crews return to work, safely, when the time comes.”

1Health.io provides testing as a service, enabling partners to easily deploy, manage, and personalize testing at scale. The company pioneered the concept first in the field of DNA testing with a simple self-administered COVID-19 saliva test that was authorized by the FDA under EUA earlier this year.

Early in the pandemic, cruise ships sitting in United States ports were identified as a high-risk environment due to the high density of passengers and crew. As cruise lines prepare for reopening in late 2020 and 2021, Future Care is prepared to assist the industry through the use of 1Health.io’s test kits both in promoting infection-free re-boarding through easy to administer self-testing conducted prior to boarding.

“We aim to make precision testing easy and accessible for everyone and have developed the first technology infrastructure that makes precision testing into a service that our partners can use to launch testing in days to any of their customers anywhere in the country,” said Mehdi Maghsoodnia, CEO of 1Health.io. “Crew members in the maritime industry, both of private cruise lines and commercial shipping, are often dispersed across the country before they meet for departure. Our saliva-based COVID-19 tests allow the crew to take the test wherever they are in the United States, so they can get back to work quickly and safely, without any delays from trying to find a testing site in a new city or lab lag times.”

The tests can be taken

CorroHealth Emerges as a Leader in Healthcare Reimbursement Solutions, Following Merger of Four Industry Players

Four healthcare services and technology organizations have launched under a combined brand—CorroHealth. TrustHCS, Visionary RCM, T-System and RevCycle+ joined forces to provide a greater breadth of reimbursement cycle, risk adjustment and quality solutions to health systems and payers. Global investment firm The Carlyle Group (NASDAQ: CG) owns a majority stake in CorroHealth, with Cannae Holdings, Inc. (NYSE: CNNE), Sanaka Group, and affiliates of TripleTree Holdings also serving as investors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005234/en/

Patrick Leonard serves as CEO of CorroHealth. (Image: CorroHealth)

CorroHealth—driven by helping clients navigate regulatory and compliance complexities to ease physician burdens and improve financial outcomes—emerges at a time when financial health is particularly important for health systems and payers.

“We knew health systems and plans would have a growing need for our solutions, so we worked hard and found a way to bring all 4,000 employees together as one company—united by our core,” said CorroHealth CEO Patrick Leonard. “At CorroHealth, we will drive results for our clients with our scalable solutions, clinical expertise, and our ability to manage across the continuum of complexity and value.”

CorroHealth combines the industry-leading domestic middle revenue cycle group of TrustHCS, with the full-service global delivery model of Visionary RCM, the emergency documentation technology solutions of T-System, and the advanced coding solutions of RevCycle+.

“Our new and unified brand name speaks to our mission to advance health by connecting people to the right solutions at the right time,” added Leonard. “We are proud of our fully integrated team and excited for the growth journey ahead.”

“We see the highly complementary nature of CorroHealth’s solutions as uniquely able to add value for health system and health plan customers,” said Joe Bress, a Principal specializing in healthcare at The Carlyle Group. “We’re excited to partner with Pat and the company’s leading management team to help build the CorroHealth platform.”

“We believe CorroHealth is well positioned for organic and inorganic growth opportunities,” added fellow Carlyle Principal James Shillito. “Carlyle and the entire investor group look forward to supporting this growth going forward.”

The four legacy company names will remain through the end of 2020 with a final move to the CorroHealth name across all companies beginning Jan. 1, 2021.

Equity capital for the investment came from the Carlyle Equity Opportunity Fund II that makes majority and strategic minority investments primarily in the U.S. in targeted industries, including healthcare.

About CorroHealth

Our core purpose is to help you exceed your financial health goals. Across the reimbursement cycle, our scalable programs and clinical expertise help solve programmatic needs. Enabling our skilled domestic and global teams with leading technology allows analytics to guide our solutions and keeps us accountable to your goals. For both health systems and plans, we navigate regulatory and compliance complexities, ease physician burdens and improve financial outcomes. We consistently deliver the right solutions at the right time.

For additional information about CorroHealth, please visit www.CorroHealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005234/en/

Contacts

Sara Payne,

Global Medicine Automated Dispensing Cabinet Market 2020 Industry Chain structure, Market Competition, SWOT Analysis Report by 2025

The MarketWatch News Department was not involved in the creation of this content.

Sep 29, 2020 (CDN Newswire via Comtex) —
The market study titled Global Medicine Automated Dispensing Cabinet Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a thorough study of the current trends leading to this vertical trend in various regions. The report describes the market by its major segments involving types, applications, and the major geographic regions. The report assesses the growth rate of the market until forecast 2025, key factors driving this market with sales, revenue, and price analysis of top manufacturers. It presents details related to market share, market size, applications, statistics, and sales. The report considers that offering an in-depth analysis of leading players is very important in order to present a market study. Therefore the report focuses on major competitors operating in this market. Next, the forecast for each product type and application segment has been provided for the 2020 to 2025 time-period has been given in the report. The market is broken down by regions, vital players, types, and applications/end-users.

Competitive Tracking:

The report offers important information related to new products launched in the global Medicine Automated Dispensing Cabinet industry, regional landscaping, various approvals, and many strategies adopted in the competitive market. Other elements such as investment feasibility investigation, investment yield analysis, potential research, rival businesses’ SWOT analyses, and market trends will also be beneficial for readers of this report. Leading players along with their market share are highlighted in the report.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT:https://www.marketquest.biz/sample-request/8296

For the competitor segment, the report includes global key players of Medicine Automated Dispensing Cabinet are included: BD, Cerner, TOSHO, Omnicell, Aesynt, Takazono, YUYAMA, Willach Group

Product type coverage (market size & forecast, a major company of product type, etc.): General Medicine Automated Dispensing Cabinet (General ADCs), Tablet ADCs, Dose ADCs, Vial ADCs

Application coverage (market size & forecast, different demand market by region, main consumer profile, etc.): Hospital, Retail pharmacies, Other

Based on segmentation, the market report is made up of an in-depth investigation of the leading regions, including: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

Some Important Deliverables of The Report:

The research comprises customer analysis, industry cost analysis, organization profiles, market analysis by application, production, revenue, and price trend analysis by type, production and consumption analysis by region, and various other market studies. Market performance is examined in terms of revenue contribution from various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing revenue growth of the global Medicine Automated Dispensing Cabinet market.

ACCESS FULL REPORT:https://www.marketquest.biz/report/8296/global-medicine-automated-dispensing-cabinet-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

The market Offers The Following Major Components:

  • An extensive study of the global Medicine Automated Dispensing Cabinet